The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
The group expects to raise nearly $170m.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.